A new study published in the Journal of Biological Chemistry from UC Davis Comprehensive Cancer Center finds that TIGIT, an immune checkpoint receptor targeted by cancer immunotherapy drugs, triggers ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback